

Alan Simon Pickard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/308865/publications.pdf>

Version: 2024-02-01

161
papers

9,285
citations

57631

44
h-index

43802

91
g-index

165
all docs

165
docs citations

165
times ranked

14817
citing authors

#	ARTICLE	IF	CITATIONS
1	Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. <i>Value in Health</i> , 2012, 15, 708-715.	0.1	1,381
2	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. <i>Quality of Life Research</i> , 2013, 22, 1717-1727.	1.5	1,082
3	Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 70.	1.0	672
4	Comparison of the EQ-5D and SF-12 Health Surveys in a General Population Survey in Alberta, Canada. <i>Medical Care</i> , 2000, 38, 115-121.	1.1	240
5	Health Utilities Using the EQ-5D in Studies of Cancer. <i>Pharmacoeconomics</i> , 2007, 25, 365-384.	1.7	232
6	Psychometric Comparison of the Standard EQ-5D to a 5 Level Version in Cancer Patients. <i>Medical Care</i> , 2007, 45, 259-263.	1.1	205
7	United States Valuation of EQ-5D-5L Health States Using an International Protocol. <i>Value in Health</i> , 2019, 22, 931-941.	0.1	204
8	Proxy Evaluation of Health-Related Quality of Life. <i>Medical Care</i> , 2005, 43, 493-499.	1.1	189
9	Validity of EQ-5D-5L in stroke. <i>Quality of Life Research</i> , 2015, 24, 845-850.	1.5	167
10	Agreement Between Patient and Proxy Assessments of Health-Related Quality of Life After Stroke Using the EQ-5D and Health Utilities Index. <i>Stroke</i> , 2004, 35, 607-612.	1.0	165
11	Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2008, 149, 380.	2.0	151
12	Health outcomes in spinal muscular atrophy type 1 following AVXSâ€101 gene replacement therapy. <i>Pediatric Pulmonology</i> , 2019, 54, 179-185.	1.0	142
13	Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. <i>International Journal of Clinical Practice</i> , 2012, 66, 1056-1078.	0.8	140
14	Assessment of Patient Functional Status after Surgery. <i>Journal of the American College of Surgeons</i> , 2005, 201, 171-178.	0.2	139
15	Responsiveness of generic health-related quality of life measures in stroke. <i>Quality of Life Research</i> , 2005, 14, 207-219.	1.5	139
16	Use of a preference-based measure of health (EQ-5D) in COPD and asthma. <i>Respiratory Medicine</i> , 2008, 102, 519-536.	1.3	126
17	Visual Analog Scales for Assessing Surgical Pain. <i>Journal of the American College of Surgeons</i> , 2005, 201, 245-252.	0.2	123
18	Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 56-65.	1.6	118

#	ARTICLE	IF	CITATIONS
19	US Valuation of Health Outcomes Measured Using the PROMIS-29. <i>Value in Health</i> , 2014, 17, 846-853.	0.1	117
20	Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 441-448.	2.0	111
21	Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. <i>Quality of Life Research</i> , 2015, 24, 1555-1563.	1.5	110
22	Replicability of SF-36 Summary Scores by the SF-12 in Stroke Patients. <i>Stroke</i> , 1999, 30, 1213-1217.	1.0	107
23	Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2019, 22, 267-275.	0.1	98
24	Comparison of US Panel Vendors for Online Surveys. <i>Journal of Medical Internet Research</i> , 2013, 15, e260.	2.1	96
25	US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. <i>Quality of Life Research</i> , 2021, 30, 803-816.	1.5	88
26	Clopidogrel-Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting. <i>Pharmacotherapy</i> , 2008, 28, 376-392.	1.2	80
27	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018, 36, 225-238.	1.7	77
28	Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 26.	1.0	73
29	Exploring Factors that Influence Informal Caregiving in Medication Management for Home Hospice Patients. <i>Journal of Palliative Medicine</i> , 2010, 13, 1085-1090.	0.6	70
30	Psychometric Properties of the EuroQol-5D and Short Form-6D in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 1209-1216.	1.0	68
31	Estimation of Patient Preference-Based Utility Weights from the Functional Assessment of Cancer Therapy General. <i>Value in Health</i> , 2007, 10, 266-272.	0.1	61
32	US Valuation of the SF-6D. <i>Medical Decision Making</i> , 2013, 33, 793-803.	1.2	60
33	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.1	58
34	Health problems are more common, but less severe when measured using newer EQ-5D versions. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 93-99.	2.4	57
35	A Structured Review of Studies on Health-Related Quality of Life and Economic Evaluation in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute Monographs</i> , 2004, 2004, 102-125.	0.9	56
36	Bisphosphonate-Induced Osteonecrosis of the Jaw. <i>Annals of Pharmacotherapy</i> , 2007, 41, 276-284.	0.9	52

#	ARTICLE	IF	CITATIONS
37	Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?. Health and Quality of Life Outcomes, 2005, 3, 11.	1.0	51
38	Evaluating Equivalency Between Response Systems. Medical Care, 2007, 45, 812-819.	1.1	51
39	A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. Journal of General Internal Medicine, 2021, 36, 1292-1301.	1.3	51
40	The societal cost of heroin use disorder in the United States. PLoS ONE, 2017, 12, e0177323.	1.1	48
41	Medication adherence and persistence in the last year of life in COPD patients. Respiratory Medicine, 2009, 103, 525-534.	1.3	47
42	Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. Value in Health, 2012, 15, 916-925.	0.1	47
43	An Update on Evidence of Clinical Pharmacy Services™ Impact on Health-Related Quality of Life. Annals of Pharmacotherapy, 2006, 40, 1623-1634.	0.9	46
44	Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease. Archives of Internal Medicine, 2009, 169, 1403.	4.3	46
45	Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. BMC Medical Research Methodology, 2014, 14, 78.	1.4	46
46	Body Image in Patients with Systemic Lupus Erythematosus. International Journal of Behavioral Medicine, 2012, 19, 157-164.	0.8	45
47	A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). Pharmacoeconomics, 2015, 33, 867-877.	1.7	45
48	The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results. Value in Health, 2022, 25, 482-491.	0.1	45
49	Stakeholder Views on Pharmacogenomic Testing. Pharmacotherapy, 2014, 34, 151-165.	1.2	43
50	A Comparison of Depressive Symptoms in Stroke and Primary Care: Applying Rasch Models to Evaluate the Center for Epidemiologic Studies-Depression Scale. Value in Health, 2006, 9, 59-64.	0.1	42
51	Comparison of FACT- and EQ-5D™-Based Utility Scores in Cancer. Value in Health, 2012, 15, 305-311.	0.1	39
52	The Impact of Pharmacist Interventions on Health-Related Quality of Life. Annals of Pharmacotherapy, 1999, 33, 1167-1172.	0.9	38
53	Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 2014, 52, 935-943.	1.1	38
54	Valuation of the EQ-5D-5L in Taiwan. PLoS ONE, 2018, 13, e0209344.	1.1	38

#	ARTICLE	IF	CITATIONS
55	The Impact of Medicare Part D on Out-of-Pocket Costs for Prescription Drugs, Medication Utilization, Health Resource Utilization, and Preference-Based Health Utility. <i>Health Services Research</i> , 2011, 46, 1104-1123.	1.0	37
56	Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer. <i>Clinical Therapeutics</i> , 2016, 38, 769-777.	1.1	37
57	Costs and Cost Effectiveness of a Health Care Providerâ€™Directed Intervention to Promote Colorectal Cancer Screening Among Veterans. <i>Journal of Clinical Oncology</i> , 2005, 23, 8877-8883.	0.8	34
58	Comparative effectiveness research: Relevance and applications to pharmacy. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 1278-1286.	0.5	34
59	A Median Model for Predicting United States Population-Based EQ-5D Health State Preferences. <i>Value in Health</i> , 2010, 13, 278-288.	0.1	32
60	Proxy Assessment of Health-Related Quality of Life in African American and White Respondents With Prostate Cancer. <i>Medical Care</i> , 2009, 47, 176-183.	1.1	31
61	Pain and depression in caregivers affected their perception of pain in stroke patients. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 963-970.	2.4	30
62	Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. <i>Value in Health Regional Issues</i> , 2014, 4, 19-23.	0.5	30
63	U.K. utility weights for the <scp>EORTC QLUâ€™10D</scp>. <i>Health Economics (United Kingdom)</i> , 2019, 28, 1385-1401.	0.8	30
64	Meta-Analysis of Azelastine Nasal Spray for the Treatment of Allergic Rhinitis. <i>Pharmacotherapy</i> , 2007, 27, 852-859.	1.2	28
65	3L, 5L, What the L? A NICE Conundrum. <i>Pharmacoeconomics</i> , 2018, 36, 637-640.	1.7	28
66	A Structured Review of the Relationship Between Microalbuminuria and Cardiovascular Events in Patients with Diabetes Mellitus and Hypertension. <i>Pharmacotherapy</i> , 2003, 23, 1611-1616.	1.2	27
67	Evaluation of content on EQ-5D as compared to disease-specific utility measures. <i>Quality of Life Research</i> , 2013, 22, 853-874.	1.5	26
68	Cost-Effectiveness of Eszopiclone for the Treatment of Adults with Primary Chronic Insomnia. <i>Sleep</i> , 2009, 32, 817-824.	0.6	25
69	Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. <i>Medical Decision Making</i> , 2018, 38, 968-982.	1.2	25
70	Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB. <i>Value in Health</i> , 2022, 25, 525-533.	0.1	25
71	Osteoarthritis: A Comorbid Marker for Longer Life?. <i>Annals of Epidemiology</i> , 2007, 17, 380-384.	0.9	24
72	Mortality Risk in Patients Receiving Drug Regimens with Theophylline for Chronic Obstructive Pulmonary Disease. <i>Pharmacotherapy</i> , 2009, 29, 1039-1053.	1.2	23

#	ARTICLE	IF	CITATIONS
73	The effect of chronic conditions on stated preferences for health. <i>European Journal of Health Economics</i> , 2013, 14, 697-702.	1.4	23
74	Pharmacoeconomics of Hematopoietic Stem Cell Mobilization: An Overview of Current Evidence and Gaps in the Literature. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1301-1309.	2.0	23
75	Patient Preferences in Prostate Cancer: A Clinician's Guide to Understanding Health Utilities. <i>Clinical Prostate Cancer</i> , 2005, 4, 15-23.	2.1	22
76	A Patient-Based Utility Measure of Health for Clinical Trials of Cancer Therapy Based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. <i>Value in Health</i> , 2009, 12, 977-988.	0.1	22
77	General population normative data for the EQ-5D-3L in the five largest European economies. <i>European Journal of Health Economics</i> , 2021, 22, 1467-1475.	1.4	22
78	Drugs Associated with Adverse Events in Children and Adolescents. <i>Pharmacotherapy</i> , 2014, 34, 918-926.	1.2	21
79	Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). <i>Value in Health</i> , 2014, 17, 744-748.	0.1	20
80	Order of Presentation of Dimensions Does Not Systematically Bias Utility Weights from a Discrete Choice Experiment. <i>Value in Health</i> , 2016, 19, 1033-1038.	0.1	20
81	Using existing data to identify candidate items for a health state classification system in multiple sclerosis. <i>Quality of Life Research</i> , 2014, 23, 1445-1457.	1.5	19
82	Emergence of BCR-ABL Kinase Domain Mutations Associated with Newly Diagnosed Chronic Myeloid Leukemia: A Meta-Analysis of Clinical Trials of Tyrosine Kinase Inhibitors. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 114-122.	0.5	19
83	Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β_2 -Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid. <i>Annals of Pharmacotherapy</i> , 2017, 51, 945-953.	0.9	19
84	EQ-5D-Y for the assessment of health-related quality of life among Taiwanese youth with mild-to-moderate chronic kidney disease. <i>International Journal for Quality in Health Care</i> , 2018, 30, 298-305.	0.9	19
85	Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off. <i>Quality of Life Research</i> , 2021, 30, 1433-1444.	1.5	19
86	Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores. <i>European Journal of Health Economics</i> , 2014, 15, 489-496.	1.4	18
87	Comparative Effectiveness of Long-Acting Beta ₂ -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease. <i>Pharmacotherapy</i> , 2017, 37, 447-455.	1.2	18
88	EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. <i>Journal of Medical Economics</i> , 2017, 20, 19-27.	1.0	18
89	The EQ-5D and the EuroQol Group. <i>Value in Health</i> , 2019, 22, 21-22.	0.1	18
90	Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. <i>Quality of Life Research</i> , 2020, 29, 2651-2660.	1.5	17

#	ARTICLE	IF	CITATIONS
91	Granulocyte Colony-Stimulating Factor for Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2005, 23, 767-775.	1.7	16
92	Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study. <i>Health Economics (United Kingdom)</i> , 2010, 19, 101-110.	0.8	16
93	The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30. <i>MDM Policy and Practice</i> , 2019, 4, 238146831984253.	0.5	16
94	Respiratory and Bronchitic Symptoms Predict Intention to Quit Smoking among Current Smokers with, and at Risk for, Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1490-1496.	1.5	15
95	A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017. <i>Quality of Life Research</i> , 2019, 28, 3065-3069.	1.5	14
96	Exploring the Internal Structure of the EQ-5D Using Non-Preference-Based Methods. <i>Value in Health</i> , 2019, 22, 527-536.	0.1	14
97	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. <i>Value in Health</i> , 2021, 24, 862-873.	0.1	14
98	Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 4.	1.0	13
99	Do health preferences contradict ordering of EQ-5D labels?. <i>Quality of Life Research</i> , 2015, 24, 1759-1765.	1.5	13
100	Engaging Patients and Caregivers to Design Transitional Care Management Services at a Minority Serving Institution. <i>Journal of Health Care for the Poor and Underserved</i> , 2016, 27, 352-365.	0.4	13
101	Transforming Latent Utilities to Health Utilities: East Does Not Meet West. <i>Health Economics (United Kingdom)</i> , 2011, 30, 107-124.	0.8	13
102	Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2019, 37, 105-116.	1.7	13
103	A Cross Sectional and Longitudinal Study of Pharmacy Student Perceptions of Readiness to Serve Diverse Populations. <i>American Journal of Pharmaceutical Education</i> , 2016, 80, 62.	0.7	12
104	Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing. <i>British Journal of General Practice</i> , 2020, 70, e589-e597.	0.7	12
105	United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument. <i>Medical Decision Making</i> , 2021, 41, 485-501.	1.2	12
106	Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ-HWB. <i>Value in Health</i> , 2022, 25, 512-524.	0.1	12
107	An Instrument to Evaluate Pharmacists' Patient Counseling on Herbal and Dietary Supplements. <i>American Journal of Pharmaceutical Education</i> , 2010, 74, 192.	0.7	11
108	Prioritizing Comparative-Effectiveness Research Topics via Stakeholder Involvement: An Application in COPD. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 888-892.	2.3	11

#	ARTICLE	IF	CITATIONS
109	Caveat Medicus: Consequences of Federal Investigations of Marketing Activities of Pharmaceutical Suppliers of Prostate Cancer Drugs. <i>Journal of Clinical Oncology</i> , 2005, 23, 8894-8905.	0.8	10
110	Complexity of Medication Use in Newly Diagnosed Chronic Obstructive Pulmonary Disease Patients. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 110-122.e1.	3.0	10
111	Patient Experience-based Value Sets. <i>Medical Care</i> , 2017, 55, 979-984.	1.1	10
112	Lifestyle-related attitudes: do they explain self-rated health and life-satisfaction?. <i>Quality of Life Research</i> , 2018, 27, 1227-1235.	1.5	10
113	Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission. <i>Journal of General Internal Medicine</i> , 2019, 34, 2029-2037.	1.3	10
114	Feasibility and acceptability of virtual academic detailing on opioid prescribing. <i>International Journal of Medical Informatics</i> , 2021, 147, 104365.	1.6	10
115	Combining EQ-5D-5L items into a level summary score: demonstrating feasibility using non-parametric item response theory using an international dataset. <i>Quality of Life Research</i> , 2022, 31, 11-23.	1.5	10
116	Design of the patient navigator to Reduce Readmissions (PARtNER) study: A pragmatic clinical effectiveness trial. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100420.	0.5	9
117	Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). <i>Journal of Blood Medicine</i> , 2012, 3, 131.	0.7	8
118	Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. <i>European Journal of Health Economics</i> , 2017, 18, 967-977.	1.4	8
119	Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 265-279.	0.5	8
120	Towards supporting scholarship in research by clinical pharmacy faculty. <i>Pharmacy Practice</i> , 2006, 4, 191-4.	0.8	8
121	The Development of the EQ-5D-5L and its Value Sets. , 2022, , 1-12.		8
122	Is it Time to Update Societal Value Sets for Preference-Based Measures of Health?. <i>Pharmacoeconomics</i> , 2015, 33, 191-192.	1.7	7
123	Practice change intentions after academic detailing align with subsequent opioid prescribing. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 1001-1008.	0.7	7
124	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021, 22, 723-733.	1.4	7
125	Developing a Valuation Function for the Preference-Based Multiple Sclerosis Index: Comparison of Standard Gamble and Rating Scale. <i>PLoS ONE</i> , 2016, 11, e0151905.	1.1	7
126	A Comparison of a Preliminary Version of the EQ-HWB Short and the 5-Level Version EQ-5D. <i>Value in Health</i> , 2022, 25, 534-543.	0.1	7

#	ARTICLE	IF	CITATIONS
127	Opportunities for Disease State Management in Prostate Cancer. <i>Disease Management: DM</i> , 2005, 8, 235-244.	1.0	6
128	Eliciting Social Preference Weights for Functional Assessment of Cancer Therapy-Lung Health States. <i>Pharmacoeconomics</i> , 2006, 24, 293-294.	1.7	6
129	Choice Blindness and Health-State Choices among Adolescents and Adults. <i>Medical Decision Making</i> , 2017, 37, 680-687.	1.2	6
130	Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 937-944.	1.3	6
131	Use of Nonpalliative Medications Following Burdensome Health Care Transitions in Hospice Patients. <i>Medical Care</i> , 2019, 57, 13-20.	1.1	6
132	Drug utilization reviews of oral quinolone, cephalosporin, and macrolide use in nonacute care: A systematic review. <i>Clinical Therapeutics</i> , 1999, 21, 1951-1970.	1.1	5
133	Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Clinics. <i>Pharmacotherapy</i> , 2004, 24, 1204-1212.	1.2	5
134	Conceptual Development of a Measure to Assess Pharmacists' Knowledge of Herbal and Dietary Supplements. <i>American Journal of Pharmaceutical Education</i> , 2008, 72, 59.	0.7	5
135	Value of transfusion independence in severe aplastic anemia from patients' perspectives – a discrete choice experiment. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 13.	0.9	5
136	Latent Class Models Reveal Poor Agreement between Discrete-Choice and Time Tradeoff Preferences. <i>Medical Decision Making</i> , 2019, 39, 421-436.	1.2	5
137	Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 19, n/a-n/a.	0.9	4
138	Comparative effectiveness and patient-centered outcomes research: enhancing uptake and use by patients, clinicians and payers. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 177-180.	0.6	4
139	The Role of Personality in Treatment-Related Outcome Preferences Among Pharmacy Students. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 6891.	0.7	4
140	Development of an Instrument to Assess the Perceived Effectiveness of Academic Detailing. <i>Journal of Continuing Education in the Health Professions</i> , 2020, 40, 235-241.	0.4	4
141	Academic detailing interventions for opioid-related outcomes: a scoping review. <i>Drugs in Context</i> , 2021, 10, 1-20.	1.0	4
142	Edmonton Quality Assessment Tool for Drug Utilization Reviews: EQUATDUR-2. <i>Medical Care</i> , 2000, 38, 948-958.	1.1	3
143	Positive Outcomes of Varicose Vein Surgery: The Patient Perspective. <i>Patient</i> , 2015, 8, 329-337.	1.1	3
144	Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. <i>European Journal of Health Economics</i> , 2021, 22, 1301-1309.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Application of directional statistics to health state valuation: A commentary on Craig and Oppe. <i>Social Science and Medicine</i> , 2010, 71, 429-430.	1.8	2
146	Using linked electronic data to validate algorithms for health outcomes in administrative databases. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 359-366.	0.6	2
147	Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets. <i>Medical Decision Making</i> , 2020, 40, 483-497.	1.2	2
148	Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality. <i>European Journal of Health Economics</i> , 2021, 22, 17-33.	1.4	2
149	Hospitalizations for opioid-related overdose and timing of concurrent opioid and benzodiazepine use: A nested case-control study. <i>Pharmacotherapy</i> , 2021, 41, 722-732.	1.2	2
150	Development of a measure of prescriber satisfaction with academic detailing: the PSAD. <i>Drugs in Context</i> , 2022, 11, 1-12.	1.0	2
151	Combating the opioid epidemic in the United States. <i>Drugs in Context</i> , 2021, 10, 1-3.	1.0	2
152	The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	1.0	2
153	RESPONSE: Re: A Structured Review of Studies on Health-Related Quality of Life and Economic Evaluation in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1786-1787.	3.0	1
154	Coded Cause of Death and Timing of COPD Diagnosis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009, 6, 41-47.	0.7	1
155	Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 167-175.	0.6	1
156	Secondary Effects of an Opioid-Focused Academic Detailing Program on Non-Opioid Controlled Substance Prescribing in Primary Care. <i>Substance Abuse</i> , 2021, 42, 962-967.	1.1	1
157	Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22102-e22102.	0.8	1
158	Importation of Prescription Medications: Experiences Opinions, and Intended Behaviors of U.S. Community Pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, 666-672.	0.7	0
159	Evaluating Equivalency Between Response Systems. <i>Medical Care</i> , 2014, 52, 385.	1.1	0
160	Time-Specific Differences in Stated Preferences for Health in the United States. <i>Medical Care</i> , 2022, Publish Ahead of Print, .	1.1	0
161	Pragmatic Clinical Trial to Improve Patient Experience Among Adults During Transitions from Hospital to Home: the PaRTNER study. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	0